Timely and relevant thoracic oncology news brought to you by the only global association dedicated to the multidisciplinary study of lung cancer.

Timely and relevant thoracic oncology news brought to you by the only global association dedicated to the multidisciplinary study of lung cancer.

SCLC Transformation

March 12, 2021

A Clinical Trial of PD-L1 Inhibitor Durvalumab and PARP Inhibitor Olaparib for Patients With EGFR-Mutated Transformed SCLC

By

Nobuyuki Takahashi, MD, PhD, et al.

Evolving Standards of Care

Discovery of targetable genomic alterations, including mutations of EGFR, have resulted in improved survival for patients with non-small cell lung cancer (NSCLC).1 Although many patients experience robust responses to EGFR-targeted […]